BRCA1 and ovarian carcinoma: In BRCA1/BRCA2 mutation carriers, PBSO/RRSO not only decreases the risk of development of ovarian cancer by 80-90 % and breast cancer by 40–50 %, but also reduces mortality due to cancer of the genital tract and overall mortality [21–24].